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Australian clinical toxicology investigators collaboration randomized trial of
different loading infusion rates of N-acetylcysteine [6]
Abstract
Adverse reactions to N-acetylcysteine are reported in 6% to 23% of patients who are administered the
antidote for treatment of paracetamol poisoning.1 Because paracetamol is the most common
pharmaceutical product taken in overdose in many countries, it is essential that attempts be made to
prevent or minimize adverse effects caused by N-acetylcysteine. We congratulate Kerr et al2 on their
attempt to address this important issue.
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Australian Clinical Toxicology Investigators
Collaboration Randomized Trial of Different
Loading Infusion Rates of N-Acetylcysteine
To the Editor:
Adverse reactions to N-acetylcysteine are reported in 6% to 23% of patients who are
administered the antidote for treatment of paracetamol poisoning.1 Because paracetamol is
the most common pharmaceutical product taken in overdose in many countries, it is
essential that attempts be made to prevent or minimize adverse effects caused by
N-acetylcysteine. We congratulate Kerr et al2 on their attempt to address this important
issue.
We would like to comment on the following.
Previous studies have shown that atopic individuals, and particularly asthmatic
individuals, are more likely to develop reactions to N-acetylcysteine.3 We do not know from
the study how many individuals in this study were atopic or asthmatic. The incidence of
asthma in Australia is recognized to be amongst the highest in world.4
Adverse reactions to N-acetylcysteine are more prevalent with low concentrations of
paracetamol in the blood of the patient being treated.3 Analysis of this risk factor for
anaphylactoid reactions would have been helpful in the study. The reactions to
N-acetylcysteine would also depend on the plasma N-acetylcysteine concentration,5 which
was not estimated in this study. A further reason for determining plasma N-acetylcysteine
concentrations is that previous studies have shown that there are often large variations in
the dose of N-acetylcysteine to patients with paracetamol poisoning caused
by administration errors.6
The endpoints measured in the study comprise various adverse events as recorded
by the treating physician. Yet classification of the reaction and whether the reaction was
drug related or not was decided independently by 2 investigators at a later date. The
potential ‘‘subjective’’ nature of this assessment is a possible source of bias. Actions taken
to treat an event have been taken into account when such classification was made. It is not
unusual for different physicians to treat the same condition differently. Furthermore, the
classification system used was one designed for adverse events associated with long-term
drug administration.
The best indicator of hepatotoxicity caused by paracetamol is International
Normalized Ratio (INR). Though measurement of alanine amino transferase (ALT) and INR
was made, maximum measured values of ALT were used to assess the efficacy of the 2
treatment arms. The baseline ALT concentration has a bearing on the maximum level
reached, and therefore the degree of increase in ALT from baseline might
have been a better indicator.
N-acetylcysteine has an elimination half-life of 5.7 hours. Adverse events were
observed every 30 minutes during the first 4 hours and at 2-, 4-, and 8-hour intervals
subsequently. Given a half-life of almost 6 hours, the results may have been different if the
observations had been made more frequently, especially in the early part of the infusion. It
would have been helpful if the adverse events after the first 15 minutes were compared
between the 2 groups because most adverse reactions seem to occur during the first 15
minutes.5

The study on N-acetylcysteine use and infusion rates probably needs to be repeated
over a long loading time and with detailed study of adverse events.
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